ASCO 2022 | I-TACKLE: IO followed by cetuximab in la/metastatic cutaneous squamous cell carcinomas

Paolo Bossi, MD, University of Brescia, Brescia, Italy, presents findings from the open-label, non-randomized Phase II I-TACKLE trial (NCT03666325) of pembrolizumab and cetuximab in patients with locally advanced/metastatic cutaneous squamous cell carcinomas (cSCC). 43 patients were enrolled and initially received pembrolizumab, with 23 patients also receiving cetuximab after acquiring resistance to pembrolizumab. The addition cetuximab resulted in 38% response with the addition of cetuxumab. Additionally, an acceptable safety profile reported. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.